These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24258099)

  • 1. Effect of fesoterodine on urethral closure function in women with stress urinary incontinence assessed by urethral pressure reflectometry.
    Klarskov N; Darekar A; Scholfield D; Whelan L; Lose G
    Int Urogynecol J; 2014 Jun; 25(6):755-60. PubMed ID: 24258099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
    Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
    J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of urethral closure function in women with stress urinary incontinence.
    Klarskov N; Scholfield D; Soma K; Darekar A; Mills I; Lose G
    J Urol; 2009 Jun; 181(6):2628-33; discussion 2633. PubMed ID: 19375093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urethral closure function in continent and stress urinary incontinent women assessed by urethral pressure reflectometry.
    Saaby ML
    Dan Med J; 2014 Feb; 61(2):B4795. PubMed ID: 24495894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urethral pressure reflectometry and pressure profilometry in healthy volunteers and stress urinary incontinent women.
    Klarskov N; Lose G
    Neurourol Urodyn; 2008; 27(8):807-12. PubMed ID: 18551560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of imipramine on urethral opening pressure: A randomized, double-blind, placebo-controlled crossover study in healthy women.
    Kornholt J; Sonne DP; Riis T; Sonne J; Klarskov N
    Neurourol Urodyn; 2019 Apr; 38(4):1076-1080. PubMed ID: 30843263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
    Staskin D; Michel MC; Nitti V; Morrow JD; Wang J; Guan Z
    Curr Med Res Opin; 2010 Apr; 26(4):813-8. PubMed ID: 20121659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urethral pressure reflectometry during intra-abdominal pressure increase-an improved technique to characterize the urethral closure function in continent and stress urinary incontinent women.
    Saaby ML; Klarskov N; Lose G
    Neurourol Urodyn; 2013 Nov; 32(8):1103-8. PubMed ID: 23532678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW; Rovner ES; Bavendam T
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of fesoterodine in women with overactive bladder.
    Sand PK; Morrow JD; Bavendam T; Creanga DL; Nitti VW
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Jul; 20(7):827-35. PubMed ID: 19495545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial.
    Wagg A; Khullar V; Michel MC; Oelke M; Darekar A; Bitoun CE
    Neurourol Urodyn; 2014 Jan; 33(1):106-14. PubMed ID: 23460503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder-wet Patients over the Age of 75 Years with Mild Cognitive Impairment.
    Rajabali S; Asaana P; Nazari S; Wagg A
    Eur Urol Focus; 2024 Mar; 10(2):325-331. PubMed ID: 38402104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
    Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
    Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.